Groundbreaking B-cell immortalization technology underpins two discovery platforms: Kling-Select and Kling-Evolve

We have pioneered the use of Bcl-xL and Bcl-6 to retrovirally transduce memory B cells producing highly efficient and stable patient derived B-cell libraries

Our unbiased screening workflow has been optimized to capture low abundance clones with desired reactivity profile against targets of interest simultaneously yielding novel targets/antibody pairs

Immortalized B cells preserve the ability to undergo activation induced somatic hypermutation allowing continuous evolution of B cell clones for increased affinity, selectivity and reactivity against alternative target variants